TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting
September 11, 2017 08:00 ET
|
TESARO, Inc.
MADRID, Spain, Sept. 11, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today provided a summary of ZEJULA and TSR-042, an anti-PD-1 antibody,...
TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
August 25, 2017 08:01 ET
|
TESARO, Inc.
WALTHAM, Mass., Aug. 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data from nine abstracts will be presented at the...
2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121
August 09, 2017 10:30 ET
|
2X Oncology, Inc.
CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan
July 27, 2017 07:00 ET
|
TESARO, Inc.
– Takeda’s Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia – TESARO to Receive $100 Million Upfront...
Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121
July 07, 2017 08:30 ET
|
2X Oncology, Inc.
HOERSHOLM, Denmark and CAMBRIDGE, Mass., July 07, 2017 (GLOBE NEWSWIRE) -- Oncology Venture AB (“Oncology Venture”) and 2X Oncology, Inc. ("2X Oncology"), today announced that Oncology Venture has...
Tesaro Announces Priority Review Designation for Niraparib NDA
December 20, 2016 08:00 ET
|
TESARO, Inc.
Niraparib New Drug Application accepted for review by FDA with a PDUFA goal date of June 30, 2017Niraparib Expanded Access Program (EAP) expected to open in U.S. in January 2017 WALTHAM, Mass., Dec. ...
Tesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian Cancer
November 01, 2016 16:30 ET
|
TESARO, Inc.
WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has completed the niraparib rolling New Drug...
TESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016
October 08, 2016 02:15 ET
|
TESARO, Inc.
Simultaneous presentation of data at ESMO and publication online in the New England Journal of MedicineTESARO Investor Webcast to be Held at 7:00 PM CET / 1:00 PM EDT COPENHAGEN, Oct. 08, 2016 ...
TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission
September 12, 2016 08:01 ET
|
TESARO, Inc.
WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...